Want to join the conversation?
Drug maker $BMY announced the early stop of its CheckMate-141 study in patients with head and neck cancer, which is the fifth early study stop with Opdivo. In 2015, three of the company's key trials with Opdivo were stopped early because of a survival advantage versus the previous standard of care. Opdivo is now approved in 46 countries.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.